
Ray Page DO PhD
Past President, The Center for Cancer and Blood Disorders
Join to view full profile
920 Santa Fe DrWeatherford, TX 76086
Phone+1 817-759-7000
Fax+1 817-759-7027
Dr. Page is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Ray Page, DO, is an oncology specialist based in Weatherford, TX. He completed his fellowship in Hematology and Medical Oncology at the University of Texas Health Science Center at Houston/M D Anderson Cancer Center. He holds a PhD in Biology (Pharmacology) from the University of North Texas and additional degrees in Physiology, Chemistry, and Biology. Dr. Page has held multiple roles, including President and Physician at The Center for Cancer and Blood Disorders, Clinical Assistant Professor at the University of Texas Southwestern Medical School, and Associate Director of Cancer Developmental Therapeutics at the Institute of Cancer Research. He is experienced in conditions such as amyloidosis and hematologic oncology and has been involved in numerous clinical trials, including those on therapies for small cell lung cancer and chronic lymphocytic leukemia.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1994 - 1997
Osteopathic Medical Center of TexasResidency, Internal Medicine, 1991 - 1994
University of North TexasPhD, Biology (Pharmacology), 1986 - 1991
Texas College of Osteopathic MedicineClass of 1991
Baylor College of DentistryMS, Physiology, 1984 - 1986
Certifications & Licensure
TX State License 1992 - 2027
AOA Board of Internal Medicine Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2013-2015
- Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2011-2014
- Distinguished Alumnus Grand Prairie High School, 2010
Clinical Trials
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
- Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
- Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Feb 05
Publications & Presentations
PubMed
- 6 citationsDeep-Learning Serial CT Prediction of Survival in Immunotherapy-Treated Non-Small Cell Lung Cancer.Chiharu Sako, Brenda F Kurland, Taly G Schmidt, Jing He, Marius De Groot
JAMA Network Open. 2026-01-02 - 16 citationsState of Professional Well-Being, Satisfaction, and Career Plans Among US Oncologists in 2023.Caroline Schenkel, Laura A Levit, Kelsey Kirkwood, Rebecca Spence, John M Burke
JCO Oncology Advances. 2025-01-01 - 1 citationsAchieving white blood cell equity: are the safety profiles of biosimilar and reference pegfilgrastims comparable?Arturo Loaiza-Bonilla, Ray D Page
Future Oncology. 2024-01-01
Journal Articles
- Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer.Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F..., N Engl J Med, 10/1/2011
- A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell...Blumenschein GR Jr, Kabbinavar F, Menon H, Mok TS, Stephenson J, Beck JT, Lakshmaiah K, Reckamp K, Hei YJ, Kracht K, Sun YN, Sikorski R, Schwartzberg L; Motesanib NSCL..., Ann Oncol, 9/1/2011
- Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.Coiffier B, Osmanov EA, Hong X, et. al, Lancet Oncol, 8/1/2011
Books/Book Chapters
Abstracts/Posters
- Medicare 2005 Demonstration Project: Patient reporting of nausea symptoms and its impact on improving quality of patient care.Mueller, B. and Page, R.D., ASCO Proceedings, 1/1/2007
- Pilot study to determine the effects of dronabinol on hot flash relief in breast cancer patients.Schrock, N., Weikel, J., Holland, L., Hiatt, M., Friess, G., and Page, R.D., Journal of the American Osteopathic Association, 1/1/2004
- Pilot study to determine the effects of dronabinol on hot flash relief in breast cancer patients.Schrock, N., Weikel, J., Holland, L., Hiatt, M., Friess, G., and Page, R.D., ASCO Proceedings, 1/1/2004
Lectures
- "Experience with Via OncologyTreatment Pathways in Community Practice"Fox-Chase Cancer Center, Philadelphia, PA - 12/1/2011
- "Prostate Cancer Update"Fort Worth, Tx - 11/1/2011
- "Cancer Prevention and Early Detection"Fort Worth, Tx - 11/1/2011
Other
- New Guidelines for the Screening of Cervical Cancer.McClennen, R., Wiggins, J., Page, R.D., Texas D.O.
10/1/2003 - Medical Oncology Fellows Home Page (Worl Wide Web/Internet)Page, R.D.
http://mda.uth.tmc.edu
1/1/1996 - Hyperthyroidism: Physical Examination findings. (Audio Visual Presentation)Page, R.D., TCOM LC Files
1/1/1993
Press Mentions
Is Cancer Care Affected by New Autism Indication for Leucovorin Amid Ongoing Shortage?February 25th, 2026
Cancer Drugs’ Sexual Toxicity Spurs “Call to Action” For OncologistsApril 15th, 2025
In Growth Spurt Since Joining OneOncology, the Center for Cancer and Blood Disorders in Fort Worth Adds 3 Practices and 14 PhysiciansJuly 12th, 2021
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: